Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The incidence of homologous recombination deficiency in metastatic triple negative breast
cancer was 52%-59%，PARP plays a key role in sensing DNA damage and converting it into
intracellular signals that activate the base excision repair (BER) and single-strand break
repair pathways. Treatment with PARP inhibitors could represent a novel opportunity to
selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. This is a
multicenter, single-arm, phase II study evaluating the efficacy and safety of niraparib in
patients with HRD positive metastatic triple negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
Fujian Cancer Hospital Hunan Cancer Hospital Sun Yat-sen University Taizhou Hospital of Zhejiang Province Zhejiang University